ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On November 26, 2019, OncoSec Medical Incorporated (the “Company”) entered into an (a) amendment, dated November 26, 2019 to the Stock Purchase Agreement and the Stockholder Agreement, each between the Company and Grand Decade Developments Limited, a British Virgin Islands limited company and a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP), dated as of October 10, 2019 (the “CGP Amendment”) and (b) amendment, dated November 26, 2019, to the Stock Purchase Agreement between the Company and Sirtex Medical US Holdings, Inc., an affiliate of CGP (“Sirtex”), dated as of October 10, 2019 (the “Sirtex Amendment” and, collectively with the CGP Amendment, the “Amendments”). The Amendments provide for, among other things, the removal of proposals from the Company’s current preliminary proxy statement for an increase in the number of the Company’s authorized outstanding shares of common stock as well as the corporate opportunity waiver. The Company’s board of directors passed resolutions to approve the corporate opportunity waiver to NRS 78.070(8).
The above description of the Amendments is a summary of certain terms and is qualified in its entirety by the full text of the Amendments which are being filed with this Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are filed as part of this report:
| 10.1 | Amendment Agreement, dated as of November 26, 2019, by and between OncoSec Medical Incorporated and Grand Decade Developments Limited. |
| 10.2 | Amendment Agreement, dated as of November 26, 2019, by and between OncoSec Medical Incorporated and Sirtex Medical US Holdings, Inc. |
ONCOSEC MEDICAL Inc Exhibit
EX-10.1 2 ex10-1.htm Exhibit 10.1 FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT AND STOCKHOLDER AGREEMENT THIS AMENDMENT (this “Amendment”) is made and entered into as of November 26,…
To view the full exhibit click here
About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.